{"nctId":"NCT00929240","briefTitle":"A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer","startDateStruct":{"date":"2009-07"},"conditions":["Breast Cancer"],"count":287,"armGroups":[{"label":"Avastin (bevacizumab)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: bevacizumab [Avastin]"]},{"label":"Avastin (bevacizumab) + Xeloda (capecitabine)","type":"EXPERIMENTAL","interventionNames":["Drug: bevacizumab [Avastin]","Drug: capecitabine [Xeloda]"]}],"interventions":[{"name":"bevacizumab [Avastin]","otherNames":[]},{"name":"capecitabine [Xeloda]","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adult patients, \\>=18 years of age;\n* HER2-negative metastatic breast cancer\n* candidates for taxane-based chemotherapy;\n* ECOG performance status of 0 or 1.\n\nExclusion Criteria:\n\n* previous chemotherapy for metastatic breast cancer;\n* prior adjuvant/neo-adjuvant chemotherapy within 6 months prior to study;\n* prior radiotherapy for treatment of metastatic disease;\n* chronic daily treatment with aspirin (325 mg/day) or clopidogrel(\\>75mg/day).","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Disease Progression or Death (Maintenance Phase Data Cutoff October 4, 2013)","description":"Progression Free Survival (PFS) was defined as the time from first study drug dosing (during the maintenance treatment phase) to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST). Progressive Disease (PD) was defined as a 20 percent (%) or greater increase in the sum of the Longest Diameter (LD) of the target lesions taking as reference the smallest sum LD recorded or appearance of new lesions.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.3","spread":null},{"groupId":"OG001","value":"75.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Progression Free Survival (Maintenance Phase Data Cutoff October 4, 2013)","description":"PFS was defined as the time from first study drug dosing to the first documented disease progression or death, whichever occurred first.Time to progression was defined as the time from randomization to the first documented disease progression defined per RECIST 1.0 criteria. Participants without an event at data cut-off or who were withdrawn from the study without documented progression were censored at the date of the last tumor assessment when the participant was known to be progression free. Participants who took other non-protocol anti-cancer drugs while being on study medication, and who were still event free were censored on the date of first dose of the anti-cancer drug. Participants without post-randomization tumor assessments but alive were censored at the time of randomization. Participants without post-randomization assessments, who died after randomization were considered to have the PFS event at date of death. Kaplan-Meier estimation was used for median time to PFS","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null},{"groupId":"OG001","value":"11.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Best Overall Confirmed Objective Response of CR or PR Per RECIST 1.0 (Maintenance Phase Data Cutoff October 4, 2013)","description":"Objective Response was determined by the investigator using modified RECIST criteria, Version 1.0. An objective response was a complete or partial overall confirmed response as determined by investigators. CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as greater than or equal to (≥) 30 % decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. Progressive disease (PD) was defined as 20% increase in the sum of the longest diameter of target lesions and SD was defined as small changes that do not meet above criteria. Pearson-Clopper one-sample method was used for Confidence intervals (CIs).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.6","spread":null},{"groupId":"OG001","value":"85.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Clinical Benefit (CR, PR and SD) Per RECIST 1.0 (Data Cutoff October 4, 2013)","description":"CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as ≥ 30 % decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. SD was defined as small changes that do not meet above criteria.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.9","spread":null},{"groupId":"OG001","value":"98.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Died (Maintenance Phase Data Cutoff October 4, 2013)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.4","spread":null},{"groupId":"OG001","value":"36.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (Maintenance Phase Data Cutoff October 4, 2013)","description":"Duration of Overall Survival (OS) was defined as the time from randomization to death of any cause. The OS data for participants for whom no death was captured in the clinical database were censored at the last time they were known to be alive. Kaplan Meier estimation was used to determine OS.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.7","spread":null},{"groupId":"OG001","value":"39.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Expected to Be Alive After 1 and 2 Years on Treatment (Maintenance Phase Data Cutoff October 4, 2013)","description":"Probability of being alive after 1 and 2 years on treatment with 95% CIs was calculated using Kaplan Meier approach with LOGLOG transformation.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.6","spread":null},{"groupId":"OG001","value":"90.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.4","spread":null},{"groupId":"OG001","value":"69.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Of Participants With PD or Death Due to PD (Maintenance Phase Data Cutoff October 4, 2013)","description":"PD was defined per RECIST 1.0 as 20% increase in the sum of the longest diameter of target lesions.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.3","spread":null},{"groupId":"OG001","value":"74.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Time To Progression (Maintenance Phase Data Cutoff October 4, 2013)","description":"Time to Progression was defined as the time from randomization to the first documented disease progression (using investigator assessments of disease progression by RECIST 1.0). PD was defined as 20% increase in the sum of the longest diameter of target lesions.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null},{"groupId":"OG001","value":"11.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life Assessed As Change From Baseline in Global Health Status Using The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - 30 (EORTC QLQ - C30) (Maintenance Phase Data Cutoff October 4, 2013)","description":"The EORTC QLQ-C30 incorporates 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social); 9 symptom scales (fatigue, pain, nausea and vomiting, dyspnoea, insomnia, appetite loss, constipation, diarrhea and financial difficulties); and a global health and quality-of-life scale. Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores were averaged and transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms. The change in global health status was determined to be the difference in values at baseline and each specific visit. The term ''baseline'' refers to the time of randomization to the maintenance phase.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.51","spread":null},{"groupId":"OG001","value":"-4.46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":null},{"groupId":"OG001","value":"-3.21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.17","spread":null},{"groupId":"OG001","value":"-5.40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.80","spread":null},{"groupId":"OG001","value":"-1.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.69","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Best Overall Confirmed Objective Response of CR or PR Per RECIST 1.0 (Initial Treatment Phase)","description":"Objective Response was determined by the investigator using RECIST criteria, Version 1.0. An objective response was a complete or partial overall confirmed response as determined by investigators. CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as ≥ 30% decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. Pearson-Clopper one-sample method was used for CI.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Clinical Benefit (CR, PR and SD) Per RECIST 1.0 (Initial Treatment Phase)","description":"CR was defined as complete disappearance of all target and non-target lesions and no new lesions. PR was defined as ≥30% decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. SD was defined as small changes that do not meet above criteria.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":78,"n":284},"commonTop":["Palmar-plantar erythrodysaesthesia syndrome","Neutropenia","Hypertension"]}}}